KR100310613B1 - Euphorbia Lathyris extract inhibiting the activity of 5a-reductase, and the cosmetic or skincare-pharmaceutical composition thereof for suppressing pimple or sebum - Google Patents
Euphorbia Lathyris extract inhibiting the activity of 5a-reductase, and the cosmetic or skincare-pharmaceutical composition thereof for suppressing pimple or sebum Download PDFInfo
- Publication number
- KR100310613B1 KR100310613B1 KR1019990028078A KR19990028078A KR100310613B1 KR 100310613 B1 KR100310613 B1 KR 100310613B1 KR 1019990028078 A KR1019990028078 A KR 1019990028078A KR 19990028078 A KR19990028078 A KR 19990028078A KR 100310613 B1 KR100310613 B1 KR 100310613B1
- Authority
- KR
- South Korea
- Prior art keywords
- sebum
- extract
- reductase
- acne
- methanol
- Prior art date
Links
- 210000002374 sebum Anatomy 0.000 title claims abstract description 44
- 206010000496 acne Diseases 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 title claims abstract description 32
- 239000002537 cosmetic Substances 0.000 title claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 18
- 229940015682 euphorbia lathyris extract Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 71
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 33
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims abstract description 18
- 229960003473 androstanolone Drugs 0.000 claims abstract description 16
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims abstract description 6
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims abstract description 5
- 238000000576 coating method Methods 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000011248 coating agent Substances 0.000 claims 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 abstract description 22
- 230000028327 secretion Effects 0.000 abstract description 18
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 239000000203 mixture Substances 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 230000002475 laxative effect Effects 0.000 abstract description 4
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000008141 laxative Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 19
- 229920000742 Cotton Polymers 0.000 description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- 239000003990 capacitor Substances 0.000 description 13
- 238000001816 cooling Methods 0.000 description 13
- 239000004744 fabric Substances 0.000 description 10
- 229960003604 testosterone Drugs 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000004821 distillation Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 239000005642 Oleic acid Substances 0.000 description 7
- 229930014626 natural product Natural products 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 239000002985 plastic film Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000004761 scalp Anatomy 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003515 testosterones Chemical class 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- MUMGGOZAMZWBJJ-JQSYSRDDSA-N (8r,9s,10r,13s,14s,17s)-17-hydroxy-10,13-dimethyl-1,2,6,7-tetratritio-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2C([3H])C([3H])C3=CC(=O)C([3H])C([3H])[C@]3(C)[C@H]21 MUMGGOZAMZWBJJ-JQSYSRDDSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 229930185597 Euphorbia lathyris Natural products 0.000 description 1
- 241001553700 Euphorbia lathyris Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000646858 Salix arbusculoides Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229910052571 earthenware Inorganic materials 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000008239 natural water Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은, 메탄올 또는 에탄올로 분리한 속수자추출물을 함유하는 것을 특징으로 하는 5α-리덕테이즈 억제제에 관한 것이다. 또한, 본 발명은 5α-리덕테이즈에 의해 생성되는 다이하이드로테스토스테론으로 인한 부작용을 억제하기 위해 메탄올 또는 에탄올로 분리한 속수자추출물을 사용하는 방법에 관한 것이다. 나아가, 본 발명은 메탄올 또는 에탄올로 분리한 속수자추출물을 함유하는, 피지억제용 또는 여드름치료용 화장료 또는 피부도포의약품에 관한 것이다.The present invention relates to a 5α-reductase inhibitor, characterized in that it contains a water extract isolated from methanol or ethanol. In addition, the present invention relates to a method of using a fastener extracted with methanol or ethanol to suppress the side effects caused by dihydrotestosterone produced by 5α-reductase. Furthermore, the present invention relates to a sebum inhibiting or acne treatment cosmetics or skin coatings containing the extract from methanol or ethanol.
상기 속수자추출물은, 5α-리덕테이즈 저해 효과가 뛰어날 뿐만 아니라 화장료 조성물로서 사람에게 사용했을 때 여드름완화 및 피지분비의 감소 효과가 우수하다. 따라서, 본 발명에 따른 속수자 추출물은 제품의 안전성 영향을 미치지 않는 농도에서 여드름 완하 효과 또는 피지분비 억제 효과가 있으므로 피지억제 화장료 또는 여드름 완하 화장료에 유효농도로 사용될 수 있고, 피부도포용 의약품의 일반적인 제형에 유효성분으로 사용될 수 있다.The water extract is not only excellent in 5α-reductase inhibitory effect, but also excellent in acne relief and sebum secretion when used as a cosmetic composition in humans. Therefore, the water extract according to the present invention has an acne laxative effect or sebum secretion inhibitory effect at a concentration that does not affect the safety of the product, so it can be used as an effective concentration in sebum inhibitory cosmetics or acne laxative cosmetics, and general dosage forms of medicines for skin application It can be used as an active ingredient in.
Description
본 발명은, 메탄올 또는 에탄올로 분리한 속수자추출물을 함유하는 것을 특징으로 하는 5α-리덕테이즈 억제제에 관한 것이다.The present invention relates to a 5α-reductase inhibitor, characterized in that it contains a water extract isolated from methanol or ethanol.
또한, 본 발명은 5α-리덕테이즈에 의해 생성되는 다이하이드로테스토스테론으로 인한 부작용을 억제하기 위해 메탄올 또는 에탄올로 분리한 속수자추출물을 사용하는 방법에 관한 것이다.In addition, the present invention relates to a method of using a fastener extracted with methanol or ethanol to suppress the side effects caused by dihydrotestosterone produced by 5α-reductase.
나아가, 본 발명은 메탄올 또는 에탄올로 분리한 속수자추출물을 함유하는, 피지억제용 또는 여드름치료용 화장료 또는 피부도포의약품에 관한 것이다.Furthermore, the present invention relates to a sebum inhibiting or acne treatment cosmetics or skin coatings containing the extract from methanol or ethanol.
5α-리덕테이즈(5α-reductase)는 피지선, 모낭, 전립선, 부고환 등의 남성 호르몬 반응성 조직에서 존재하며, 남성 호르몬들 중 하나인 테스토스테론(Testosterone)을 다이하이드로테스토스테론(Dihydrotestosterone:DHT)으로 환원시키는데 관여하는 효소로서 그 전환에는 엔에이디피에치(NADPH)를 필요로 한다. 남성 성충동, 골격근 증가, 남성외부생식기, 음낭성장, 정자형성 등에는 테스토스테론이 관여하고, 여드름, 피지증가 및 전립선비대증 등에는 다이하이드로테스토스테론이 해당 조직에서 관여 한다(Diane et al; J.I.D. 775-778, 1995. Bruchovsky,N et al; J.B.C. 243, 2112-2121, 1968). 따라서, 5α-리덕테이즈 효소의 억제제를 사용하여 여드름 치료제 및 피지분비 억제제를 개발하려는 연구들이 활발이 진행되고 있다.5α-reductase is present in testosterone-reactive tissues such as sebaceous glands, hair follicles, prostate, and epididymis, and reduces testosterone, one of the testosterones, to dihydrotestosterone (DHT). As an enzyme involved, its conversion requires NDPH (NADPH). Testosterone is involved in male sexual impulses, skeletal muscle growth, male external genitalia, scrotum growth, and spermatogenesis, while dihydrotestosterone is involved in acne, sebum and prostatic hyperplasia (Diane et al; JID 775-778, 1995. Bruchovsky, N et al; JBC 243, 2112-2121, 1968). Therefore, studies are actively underway to develop acne treatment and sebum secretion inhibitors using inhibitors of 5α-reductase enzyme.
일반적으로 두피 및 얼굴을 포함한 피부에서 피지는, 피부의 보습유지나 미생물의 침입을 막는 역할을 담당하지만, 사춘기 이후에는 여드름을 촉진시킨다. 특히, 30대 이후의 여성의 경우에는 피지의 과분비로 피부의 번들거림, 화장의 들뜸 및 모공의 넓어짐을 유발하기도 한다. 피지 과분비가 일어나는데는 여러 원인이 관여하고 있는데, 그 중에서도 가장 중요한 요인은 피지선의 활성에 있어 피지 분비를 촉진하는데 관여하는 호르몬 가운데 하나인 다이하이드로테스토스테론의 양에 의해서 피지선의 세포가 활성화되어 피지 과분비가 일어난다고 알려져 있다.In general, sebum in the skin, including the scalp and face, plays a role in moisturizing the skin and preventing invasion of microorganisms, but promotes acne after puberty. In particular, women in their 30s and older may cause skin bloating, lifting of makeup, and widening of pores due to excessive secretion of sebum. Sebaceous hypersecretion is caused by a number of causes, the most important of which is the sebaceous gland is activated by the amount of dihydrotestosterone, one of the hormones involved in promoting sebum secretion, sebum hypersecretion It is known to happen.
여드름은 여러 원인이 복합적으로 관여하는데, 사춘기의 남성 호르몬 기능항진으로 피지선의 분비가 왕성해지고 모낭의 상피세포가 이상각화증을 일으켜 모낭이 막히고 이로인해 여드름의 기본 병변인 면포가 형성된다. 모낭 내에 상주하는 균은 자유-지방산(free fatty acid)을 생성하여 이것이 모낭을 자극하여 염증을 유발한다. 이러한 여드름으로의 진행은 피지 과분비로 인해 더욱 악화된다.Acne is a complex cause of various causes, such as pubertal hyperactivity of the sebaceous glands secrete vigorously, epithelial cells of the hair follicles cause dyskerosis, clogging the hair follicles, which forms the scleroderma, which is the primary lesion of acne. Bacteria that reside in hair follicles produce free fatty acids, which stimulate hair follicles to cause inflammation. This progression to acne is exacerbated by sebum oversecretion.
이러한 남성 호르몬 억제로 인한 여드름 치료를 위해, 종래에는 에스트로겐등의 여성 호르몬을 사용하거나 5α-리덕테이즈 억제제를 이용해왔다. 그러나 이러한 여성 호르몬제등은 여드름 치료 효과외에, 피부 염증 발생, 호르몬 투여에 의한 부작용 발생 등이 보고되고 있어, 현재는 사용을 중단하거나 아주 극미량을 사용하고 있는 실정이다. 한편, 피지 과분비를 억제하는 여드름 치료제로, 5α-리덕테이즈의 억제제인 아젤레익 산(azelaic acid )을 15-20과량 함유한 제제로 시판되고 있다.For the treatment of acne caused by this testosterone suppression, female hormones such as estrogen or the like have been used or 5α-reductase inhibitors. However, such female hormones, in addition to the acne treatment effect, skin inflammation, side effects caused by the hormone has been reported, and the current situation is discontinued or use a very small amount. On the other hand, as an acne treatment agent that inhibits sebum oversecretion, it is commercially available as a formulation containing 15-20 excess of azelaic acid, an inhibitor of 5α-reductase.
한편, 화장품분야에서도 피지의 과분비는 화장의 들뜸이나 모공이 넓어지게 하는 요인으로서 중요한 관심의 대상임에도 불구하고, 그 연구가 미미한 실정이다. 현재 피지억제 화장품은, 일시적으로 피지를 흡착시키는 다공성 파우더를 사용하거나, 기존에 피지를 억제한다고 알려진 생약 추출물인 아이비 추출물 등을 화장품 원료로 사용하고 있으나, 그 효과는 미미한 정도이다.On the other hand, even in the cosmetic field, sebum oversecretion is an important subject of interest as a factor that causes the lifting of the makeup and widening of the pores, the research is insignificant. Currently, sebum inhibitory cosmetics use a porous powder that temporarily adsorbs sebum or ivy extract, which is a herbal extract known to inhibit sebum, as a cosmetic raw material, but its effect is minimal.
본 발명은, 이러한 현실을 감안하여 이미 알려져 있는 피지억제 물질의 문제점을 극복하고자 하는 연구의 일환으로 천연물들 중에서 유효물질을 검색하여, 5α-리덕테이즈의 저해효과를 나타내는 천연물의 추출물을 찾고자 하였으며, 이러한 천연물 추출물이, 여드름 감소 효과 또는 피지분비 감소 효과가 있는지 확인하고자 하였다.The present invention, in view of this reality as part of the research to overcome the problems of the known sebum inhibitory substance was searched for an active substance among natural products, to find an extract of natural products exhibiting the inhibitory effect of 5α-reductase. To determine whether these natural extracts have an acne reduction or sebum secretion effect.
본 발명은, 메탄올 또는 에탄올로 분리한 속수자추출물을 함유하는 것을 특징으로 하는 5α-리덕테이즈 억제제에 관한 것이다.The present invention relates to a 5α-reductase inhibitor, characterized in that it contains a water extract isolated from methanol or ethanol.
또한, 본 발명은 5α-리덕테이즈에 의해 생성되는 다이하이드로테스토스테론으로 인한 부작용을 억제하기 위해 메탄올 또는 에탄올로 분리한 속수자추출물을 사용하는 방법에 관한 것이다.In addition, the present invention relates to a method of using a fastener extracted with methanol or ethanol to suppress the side effects caused by dihydrotestosterone produced by 5α-reductase.
나아가, 본 발명은 메탄올 또는 에탄올로 분리한 속수자추출물을 함유하는, 피지억제용 또는 여드름치료용 화장료 또는 피부도포의약품에 관한 것이다.Furthermore, the present invention relates to a sebum inhibiting or acne treatment cosmetics or skin coatings containing the extract from methanol or ethanol.
본 발명자는, 피지분비, 여드름생성 등을 유발한다고 알려져 있는 다이하이드로테스토스테론의 양을 조절하고자, 다이하이드로테스토스테론의 생성을 촉매하는 효소인 5α-리덕테이즈의 활성을 억제하는 천연추출물을 찾고자 하였다.The present inventors have tried to find a natural extract that inhibits the activity of 5α-reductase, an enzyme catalyzing the production of dihydrotestosterone, in order to control the amount of dihydrotestosterone known to cause sebum secretion and acne production.
속수자를 포함하여 300여종의 여러 천연식물 추출물을 이용하여, 시험관내(in vitro)에서 5α-리덕테이즈의 활성을 저해하는지를 실험한 결과, 속수자 추출물이 5α-리덕테이즈의 억제제 역할을 한다는 것을 발견하였다[실험 1 참조].Using 300 extracts of several natural plants, including Succulents, to determine whether they inhibit the activity of 5α-Reductase in vitro, we found that Succulent Extracts act as inhibitors of 5α-Reductase. Found (see Experiment 1).
이를 기초로 하여, 본 발명자는 속수자 추출물을 이용하여 여드름 감소, 피지분비 감소를 실험한 결과, 속수자 추출물이 우수한 효과를 나타내고 있다는 것을 발견하였다[실험 2 내지 4 참조].On the basis of this, the present inventors have found that the water extract is showing an excellent effect as a result of acne reduction and sebum secretion using the water extracts [see Experiments 2 to 4].
따라서, 본 발명은 메탄올 또는 에탄올로 분리한 속수자추출물을 5α-리덕테이즈의 활성을 저해하는데 사용하고자 하며, 나아가, 이러한 속수자추출물을 여드름 감소 및 피지분비 감소하는데 사용하고자 한다.Therefore, the present invention intends to use the extracts isolated from methanol or ethanol to inhibit the activity of 5α-reductase, and furthermore, the extracts are used to reduce acne and sebum secretion.
본 발명에 따른 속수자추출물에 대하여 자세히 설명하고자 한다.It will be described in detail with respect to the water extract according to the present invention.
속수자(생약명:Euphorbiae Lathyridis Semen; 식물명: Euphorbia Lathyris L)는 천금자, 천량금 또는 백수자 이라고도 하며 2 년생 초목으로 1m 정도 곧게 자라며 버들잎 모양의 잎을 지니고 가지를 많이 치며 유즙이 있는 식물이다. 이 식물은 4-7월에 꽃이 피며 과기는 7-8월이고, 종자는 타원형으로서 길이는 5-6 ㎜ 이고 직경은 4 ㎜정도이며 내면은 광택이 있다. 예로부터 속수자는 수종장만, 간성복수, 이편불통, 월경, 식중독, 독충에 작용이 있어서 환으로 먹기도 하거나 짓찧어 환처에 붙이기도 한다(원색천연약물대사전, 남산당 1989). 알려진 주요 성분으로 씨에는 기름 40-48, 쿠마린성분인 다프네린과 에스쿨레틴 0.6, 비쿠마린상분으로서 파두의 설사 성분과 비슷한 물질인 에우폴, α-에우포르볼, 이소에우포를, 에우포르베틴, 이소에우포르베린 등 트리테르페노이드가 있다(약초의 성분과 이용, 일월서각, 1991).The abbreviation (Euphorbiae Lathyridis Semen; botanical name: Euphorbia Lathyris L), also known as sperm, larva or white, is a biennial vegetation, grows about 1m straight, has a willow leaf shape, has many branches, and is succulent. The plant blossoms in April-July, the fruit is July-August, the seeds are elliptical, 5-6 mm long, 4 mm in diameter and glossy on the inside. Since ancient times, the deceased has the effect on the long bowel, hepatic pluripotency, dysplasia, menstruation, food poisoning, and poisonous insects. The main known ingredients include oils 40-48, coumarin-based daphrine and esculletin 0.6, bicoumarin-like substances eupol, α-euphorball and isoeupo, similar to Phadu's diarrhea. Triterpenoids such as betin and isoeuphorin (the ingredients and their use in herbal medicine, Jangwolseo, 1991).
본 발명에 따라, 메탄올 또는 에탄올로 분리하는 속수자 추추물의 추출 및 농축방법을 상세히 살펴보면 다음과 같다.According to the present invention, a method of extracting and concentrating a water extract of water separated by methanol or ethanol is described in detail as follows.
속수자 천연물 또는 생약을 분쇄한 후, 무수 저급 알코올인 에탄올 또는 메탄올을 추출용매로 하여, 속수자로부터 유효성분을 추출한다.After crushing the natural product or the herbal medicine, the active ingredient is extracted from the natural water by using ethanol or methanol which is anhydrous lower alcohol as an extraction solvent.
속수자 성분들을 최대한 용출하기 위해서는, 세포막을 파괴할 수 있는 메탄올을 추출용매로 하는 것이 바람직하다.In order to maximize the elution component, it is preferable to use methanol as the extraction solvent, which can destroy the cell membrane.
유효성분들이 증발되는 것을 막기 위하여 냉각콘덴서가 장치되어 있는 상태에서, 각 추출용매의 적정온도범위에서 가열하여 추출하는 것이 바람직하다.In order to prevent the effective components from evaporating, it is preferable to extract by heating in the appropriate temperature range of each extraction solvent in the state that the cooling capacitor is equipped.
메탄올의 적정온도는 50-80℃이고, 에탄올의 적정온도는 65℃이다.The titration temperature of methanol is 50-80 캜, and the titration temperature of ethanol is 65 캜.
한편, 유효성분이 파괴되지 않으면서 용출량이 가장 많도록 하기위해 2시간동안 가열하여 추출하는 것이 바람직하다.On the other hand, it is preferable to extract by heating for 2 hours in order to maximize the amount of elution without destroying the active ingredient.
속수자에 추출용매를 가하여 분리되어 나온 추출물을 하루동안 상온에서 방치하여 불순물을 침전시킨 후, 와트만 필터 페이퍼로 필터링하여 불순물을 제거하는 것이 바람직하다. 이 때, 속수자 추출물은 맑고 노란색과 녹색의 성상을 띤다.It is preferable to remove the impurities by adding the extraction solvent to the inner water and leaving the separated extract at room temperature for one day to precipitate impurities, and then filtering with a wattman filter paper. At this time, the extract is clear and yellow and green in appearance.
속수자 추출물을 농축하기 위해 증류장치를 이용하여 증발되어 나오는 용매를 회수한다. 이 때, 추출물의 유효성분들이 증발하는 것을 막기 위해 냉각콘덴서가 달린 증류장치를 이용하는 것이 바람직하다.To evaporate the solvent, the solvent is recovered by evaporation using a distillation apparatus. At this time, it is preferable to use a distillation apparatus with a cooling capacitor in order to prevent the active ingredients of the extract from evaporating.
상기 속수자추출물을 더욱 농축하기 위해, 상기 속수자추출물에, 물과 에칠아세테이트로 이루어진 용매 또는 물과 부탄올로 이루어진 용매를 섞어, 추출용매에 의해 용출된 속수자의 수용성 성분들과 비수용성 성분들을 모두 녹이고, 층을분리시킨 후, 에칠아세테이트층 또는 부탄올층을 회수한다.In order to further concentrate the water extract, the water extract is mixed with a solvent consisting of water and ethyl acetate or a solvent consisting of water and butanol, and dissolving both water-soluble and non-aqueous components of the water eluted by the extraction solvent, After separating the layers, the ethyl acetate layer or the butanol layer is recovered.
분획시 물층보다 상층액의 에칠아세테이트층 또는 부탄올층에 유효성분들이 과량 검출되므로, 상층액을 분리하여 냉각콘덴서가 달려있는 증류장치를 이용하여 증발되어 나오는 에칠아세테이트 또는 부탄올를 회수하고, 감압농축된 액상의 속수자 농축액을 수득한다. 속수자추출물을 화장료에 적용할 때는 에칠아세테이트 또는 부탄올을 완전히 제거하여 냄새가 없도록 하여야 한다.In the fractionation, the excess of the active ingredient is detected in the ethyl acetate layer or the butanol layer of the supernatant rather than the water layer, and the supernatant is separated to recover the ethyl acetate or butanol that is evaporated using a distillation apparatus equipped with a cooling capacitor, and the concentrated liquid is concentrated under reduced pressure. Obtain an aqueous solution of. When applying water extract to cosmetics, ethyl acetate or butanol should be completely removed to avoid odor.
속수자추출물에 침전되어 있는 왁스를 제거시키기 위해 에드벤텐상의 필터페이퍼를 사용하여 진공상태에서 여과시켜서 왁스를 제거하고, 액상만 투과함으로서 액상만 분리하는 것이 바람직하다. 화장료에 속수자추출물을 첨가할 경우 왁스가 많이 남아있는 경우 제형에 문제가 될 수 있기 때문이다.In order to remove the wax deposited on the extract, it is preferable to remove the wax by filtration in vacuo using an edbenten-like filter paper and to separate only the liquid phase by penetrating only the liquid phase. This is because the addition of water-soluble extract in the cosmetics may cause problems in the formulation if a lot of wax is left.
상기와 같은 방법으로 분리되거나 더 나아가 농축된 속수자추출물은, 501,3-부틸렌글리콜 및 10에탄올에 녹여, 유연화장수, 영양화장수, 마사지 크림, 에센스, 팩 등과 같은 화장료에 첨가하여 사용할 수 있다. 또한, 상기 속수자추출물은 피부도포용 의약품의 일반적인 제형에 유효성분으로 사용될 수 있다.The water extract isolated or further concentrated in the above manner is dissolved in 501,3-butylene glycol and 10 ethanol, and can be used by adding to cosmetics such as softening water, nutrient cosmetics, massage cream, essence, pack, and the like. In addition, the extract may be used as an active ingredient in the general formulation of the drug for skin application.
아래에서는 실시예 및 실험을 통해 본 발명을 구체적으로 살펴보고자 한다. 그러나, 상기 실시예 및 실험에 의해서 본 발명의 범위가 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail through examples and experiments. However, the scope of the present invention is not limited by the above examples and experiments.
[실시 예 1; 속수자 추출물의 제조][Example 1; Preparation of Succulent Extracts]
(1) 속수자 천연물은 분쇄과정을 거쳐서 건조 중량(㎏)에 메탄올을 1:1의 비(w/v)로 가하고 난 후, 냉각콘덴서가 장치되어 있는 상태에서, 65 ℃에서, 2시간동안 가열하여 속수자의 유효성분을 추출하였다. 이로부터 나온 1차 추출물을 보관하였다.(1) Fastener natural product is pulverized, and added methanol to dry weight (kg) in a ratio of 1: 1 (w / v), and then heated at 65 ° C. for 2 hours with a cooling capacitor. By extracting the active ingredient of the recipient. The primary extract from this was stored.
(2) 1차 추출물을 덜어낸 (1)번의 속수자 천연물의 건조중량(㎏)에 다시 메탄올을 1:1의 비(w/v)로 첨가하여, 냉각콘덴서가 장치되어 있는 상태에서 상기 (1)의 과정을 반복하여, 속수자의 유효성분들을 최대한 추출하였다(2차 추출물).(2) Methanol was added to the dry weight (kg) of the fastener natural product (1) from which the primary extract was removed in a ratio of 1: 1 (w / v), and in the state where the cooling capacitor was installed (1) ) Process was repeated, extracting the active ingredients of the beneficiary as much as possible (secondary extract).
(3) 상기 1차 추출물과 2차 추출물을 섞은 후, 하루동안 상온에서 방치하여 불순물을 침전시킨 후, 와트만 필터 페이퍼 2번으로 2회 필터링하여 불순물을 완전히 제거하였다. 이 때, 속수자 추출물은 맑고 노란색과 녹색의 중간 성상을 띠었다.(3) After mixing the primary extract and the secondary extract, it was left at room temperature for one day to precipitate impurities, and then filtered twice with No. 2 filter paper Whatman to completely remove impurities. At this time, the extract was shown to be a clear yellow to green intermediate.
(4) 냉각콘덴서가 달린 증류장치를 이용하여 (3)에서 나온 추출물을 증발시켜 이로부터 나오는 용매를 회수하여, 완전히 감압농축된 속수자추출물을 얻었다.(4) The extract obtained in (3) was evaporated using a distillation apparatus equipped with a cooling capacitor to recover the solvent from it, and the extract was completely concentrated under reduced pressure.
(5) 상기 감압농축된 속수자추출물에, 물과 에칠아세테이트를 1:1로 섞은 용매 3부피를 첨가하여, 완전히 혼탁화시켰다. 이렇게 혼탁화시킴으로써 메탄올에 의해 용출된 수용성 성분들과 비수용성 성분들을 모두 녹인 후, 하루동안 방치시켜, 층을 분리시켰다. 상층액인 에칠아세테이트층을 분리하여 냉각콘덴서가 달려있는 증류장치를 이용하여 증발되어 나오는 에칠아세테이트를 회수하고, 완전히 감압농축된 액상의 속수자농축액을 수득하였다.(5) To the depressurized extract, 3 volumes of a solvent mixed with water and ethyl acetate in a 1: 1 ratio were added to complete turbidity. This turbidity dissolved both the water-soluble and water-insoluble components eluted with methanol and left for one day to separate the layers. The ethyl acetate layer as a supernatant was separated, and the ethyl acetate extracted by evaporation was recovered using a distillation apparatus equipped with a cooling capacitor, to obtain a rapid depressurized liquid concentrate completely concentrated under reduced pressure.
(6) 에드벤텐상의 필터페이퍼를 사용하여 속수자 농축액을 진공상태에서 여과시켜서 왁스를 제거하고, 투과한 액상만 분리하였다.(6) The fastener concentrate was filtered in vacuo using an adbenten-like filter paper to remove wax, and only the permeate liquid phase was separated.
최종적으로 속수자 액상 추출물 0.05∼0.2를 수득하였다(시료 1).Finally, 0.05 to 0.2 of the aqueous extract was obtained (Sample 1).
[실시예 2; 속수자 추출물의 제조][Example 2; Preparation of Succulent Extracts]
속수자 천연물의 건조 중량(㎏)에 70에탄올을 1:1의 비(w/v) 가하고 난 후, 냉각콘덴서가 장치되어 있는 상태에서 65℃로 2시간 가열하여 속수자의 유효성분을 추출하였다. 냉각콘덴서가 달린 증류장치를 이용하여 상기 속수자추출물을 증발시켜 이로부터 나오는 용매를 회수하여, 완전히 감압농축되고 건조된 속수자추출물을 수득하였다.70 ethanol was added to the dry weight (kg) of the fastener natural product in a ratio of 1: 1 (w / v), and the active ingredient of the fastener was extracted by heating at 65 ° C. for 2 hours while the cooling capacitor was installed. The fastener extract was evaporated using a distillation apparatus equipped with a cooling capacitor to recover the solvent from the fastener extract, thereby obtaining a concentrated extractor which was completely concentrated under reduced pressure.
이것에 다시 에칠아세테이트와 물을 1:1의 비율로 섞어 층을 분리한 후, 에칠아세테이트층 부분만 취해 냉각콘덴서가 달린 증류장치를 이용하여 증발되어 나오는 에칠아세테니트를 회수하면서, 완전히 감압 농축된 액상의 속수자농축액을 수득하였다. 에드벤텐상의 필터페이퍼를 사용하여 속수자 농축액을 진공상태에서 여과시켜서 왁스를 제거하고, 투과한 액상만 분리하였다.The mixture is then mixed with ethyl acetate and water in a ratio of 1: 1, and the layers are separated, and only the portion of the ethyl acetate layer is taken out and concentrated under reduced pressure while recovering the ethyl acetate which is evaporated using a distillation apparatus equipped with a cooling capacitor. A water extract of the prepared liquid was obtained. The adjuvant concentrate was filtered in vacuo using an adbenten-like filter paper to remove the wax, and only the permeated liquid phase was separated.
이로부터 속수자 농축액 0.3-0.5을 수득하였다(시료 2).This resulted in 0.3-0.5 fastener concentrate (Sample 2).
[실시예 3; 속수자 추출물의 제조][Example 3; Preparation of Succulent Extracts]
속수자 천연물 건조 중량(㎏)에 50에탄올을 1:1의 비(w/v) 가하고 난 후, 냉각콘덴서가 장치되어 있는 상태에서 65℃로 2시간 가열하여 속수자의 유효성분을추출하였다. 냉각콘덴서가 달린 증류장치를 이용하여 상기 속수자추출물을 증발시켜 이로부터 나오는 용매를 회수하여, 완전히 감압농축되고 건조된 속수자추출물을 수득하였다.50ethanol was added 1: 1 (w / v) to the dry weight of the fastener natural product (kg), and the active ingredient of the fastener was extracted by heating at 65 ° C. for 2 hours while the cooling capacitor was installed. The fastener extract was evaporated using a distillation apparatus equipped with a cooling capacitor to recover the solvent from the fastener extract, thereby obtaining a concentrated extractor which was completely concentrated under reduced pressure.
이것에 다시 에칠아세테이트보다 좀더 비극성인 부탄올과 물을 1:1의 비율로 섞어 층을 분리한 후, 부탄올층 부분만 취해 냉각콘덴서가 달린 증류장치를 이용하여 증발되어 나오는 부탄올을 회수하면서, 완전히 감압농축된 액상의 속수자농축액을 수득하였다. 에드벤텐상의 필터페이퍼를 사용하여 속수자 농축액을 진공상태에서 여과시켜서 왁스를 제거하고, 투과한 액상만 분리하였다.This was again mixed with non-polar butanol and water more than ethyl acetate in a ratio of 1: 1, and the layers were separated, and only the part of the butanol layer was taken out and recovered by evaporation of butanol using a distillation apparatus equipped with a cooling capacitor. A concentrated aqueous solution was obtained. The adjuvant concentrate was filtered in vacuo using an adbenten-like filter paper to remove the wax, and only the permeated liquid phase was separated.
이로부터 0.1-0.3의 속수자농축액을 수득하였다(시료 3).From this, a water concentrate of 0.1-0.3 was obtained (sample 3).
[실시 예 4; 유연화장수][Example 4; Soft Cosmetics]
실시예 1의 속수자추출물(시료 1)을 함유한 피지억제 영양 화장수를 표 1의 처방 예에 따라 제조하였다.Sebum inhibitory nutrition lotion containing the extract of Example 1 (Sample 1) was prepared according to the formulation example of Table 1.
<실험 1; 속수자 추출물의 5α-리덕테이즈 저해 효과 시험>Experiment 1; 5α-Reductase Inhibitory Effect Test of Sokja Extract>
속수자추출물이 5α-리덕테이즈의 활성을 제해하는 억제제인지를 확인하고자 다음과 같은 실험을 수행하였다.In order to confirm whether the extracts are inhibitors that inhibit the activity of 5α-reductase, the following experiment was performed.
1) 성숙한 스프레그-다올리쥐(Sprogue-Dawley rat) 수컷(생후 7-8주)을 디에칠이서로 치사시키고 나서, 복부 전립선을 떼내어 결합조직을 제거한 것에 0.32M 수크로스(sucrose), 0.1mM 다이티오트레이톨(dithiothreitol), 20mM 초산나트륨(sodium acetate)을 함유하는 완충액을 첨가하여 잘게 자른 후 분쇄기로 현탁화하였다. 상기 현탁액을 원심 분리한 후, 상층액을 취하였다. 이러한 상층액에는 5α-리덕테이즈가 부분정제되어 있다.1) A male Sprogue-Dawley rat (7-8 weeks of age) was killed with a deciduous rat, and then 0.32M sucrose in which the abdominal prostate was removed to remove connective tissue. A buffer containing 0.1 mM dithiothreitol, 20 mM sodium acetate, was added, finely chopped and suspended in a grinder. After centrifugation of the suspension, the supernatant was taken. 5α-reductase is partially purified in this supernatant.
2) 위에서 얻은 상층액의 일부를 취하여 0.2M 1염기성(monobasic)과 0.2M 2염기성(dibasic)이 들어 있는 완충액에 넣었다.2) A portion of the supernatant obtained above was taken and placed in a buffer containing 0.2M monobasic and 0.2M dibasic.
3) pH 6.5로, 1mM 다이티오트레이톨, 40mM 나트륨 포스페이트(Sodium Phosphate), 50μM 엔에이디피에치(NADPH), 2.2×109M [1,2,6,7-3H] 테스토스테론/테스토스테론을 함유한 반응용액 565㎕을 준비하였다.3) pH 6.5, 1mM hit by a die thio tray tolyl, ADP 40mM sodium phosphate (Sodium Phosphate), 50μM yen (NADPH), 2.2 × 10 9 M [1,2,6,7- 3 H] testosterone / testosterone 565 µl of the reaction solution was prepared.
4) 실시예 1 내지 3에서 수득된 속수자추출물(시료 1 내지 3)을 각각 10에탄올에 0.1가 되도록 녹인 후, 3)번의 반응용액에 5.65㎕첨가하여, 최종농도가 0.001가 되도록 하였다.4) The water extracts (samples 1 to 3) obtained in Examples 1 to 3 were dissolved in 10 ethanol to 0.1, respectively, and then 5.65 µl was added to the reaction solution of 3) to obtain a final concentration of 0.001.
대조군으로, 속수자추출물을 첨가하지 아니한 10에탄올 5.65㎕을 상기 3)번의 반응용액 565㎕에 첨가하였다.As a control, 5.65 [mu] l of 10 ethanol without the addition of the extract was added to 565 [mu] l of the reaction solution of step 3).
5) 1)에서 부분정제한 2)의 효소 현탁액 0.8㎎을 마지막으로 넣자마자 37℃에서 30분간 반응을 진행시켰다.5) As soon as 0.8 mg of the enzyme suspension of 2) partially purified in 1) was finally added, the reaction proceeded at 37 ° C. for 30 minutes.
6) 그리고 나서, 1㎖의 에칠아세테이트를 가하여 혼탁화시키면, 상층액에 동위원소가 붙은 테스토스테론과 다이하이드로테스토스테론이 분리되어 있다. 상층액 100㎕의 에칠아세테이트상을, 전개 용매계를 에칠아세테이트-사이클로 핵산(1:1)으로 하여 실리카 플라스틱 시트 카이젤겔 60 에프 254(Silica plastic sheet kieselgel 60 F254)위에서 전개하였다. 이러한 과정을 통해, 5-α리덕테이즈에 의해 테스토스테론으로부터 전환된 다이하이드로테스토스테론은 테스토스테론과 이동거리차에 의해 분리되어 나타났다.6) Then, when 1 ml of ethyl acetate is added and clouded, the isotopic testosterone and dihydrotestosterone are separated from the supernatant. An ethyl acetate phase of 100 µl of the supernatant was developed on silica plastic sheet kieselgel 60 F254 using the developing solvent system as ethyl acetate-cyclonucleic acid (1: 1). Through this process, dihydrotestosterone converted from testosterone by 5-α reductase was separated from testosterone by the difference in distance.
플라스틱 시트를 공기에 건조한 후, 동위원소의 양을 측정하기 위해 바스 시스템을 사용하였다. 즉, 건조된 플라스틱 시트와 엑스레이 필름을 바스 카세트에 함께 넣어 1주일 동안 보관한 후에 필름에 남아있는 테스토스테론과 다이하이드로테스토스테론의 동위원소 양을 측정하였다.After drying the plastic sheet in air, the bath system was used to measure the amount of isotopes. That is, the dried plastic sheet and the X-ray film were put together in the bath cassette and stored for one week, and then the amount of isotopes of testosterone and dihydrotestosterone remaining in the film was measured.
7) 실험은 2차에 걸쳐 반복적으로 하였다.7) The experiment was repeated two times.
8) 5α-리덕테이즈 활성을 측정하기 위해, 기질 테스토스테론[3H]로부터 다이하이드로테스토스테론[3H]의 생성정도를 측정하였다.8) 5α- deokte Li order to measure the rise activity was measured generation amount of testosterone substrate [3 H] dihydro testosterone [3 H] from.
상기, 측정 데이터를 토대로 시료 1 내지 3 각각에서 5α-리덕테이즈 활성의저해율에 대한 결과는 표 2에 나타내었다. 불순물이나 기질의 자연적 분해에 의해 의한 오차를 제거하기 위해 효소를 가하지 않은 상태의 기질대조군 값을 각각의 효소저해 활성검색 결과에서 빼주는데 일반적인 기질대조군 값은 2미만이었다.Based on the measurement data, the results for the inhibition rate of 5α-reductase activity in each of Samples 1 to 3 are shown in Table 2. In order to remove the errors caused by the natural degradation of impurities or substrates, the substrate control values without enzymes were subtracted from the results of the enzyme inhibition activity screening.
* T : 테스토스테론 영역에서 나타난3H 방사능(radio activity)* T: 3 H radio activity in the testosterone region
DHT : 다이하이드로테스토스테론 영역에서 나타난3H 방사능DHT: 3 H radioactivity in the dihydrotestosterone region
* 전환율 : DHT 영역의 방사능/전체 방사능* Conversion rate: Radioactivity / total radiation in DHT area
저해율(): 100 ×(대조군의 전환율-시료의 전환율)/대조군의 전환율Inhibition Rate (): 100 × (Conversion Rate-Sample Conversion Rate) / Control Rate
이상의 결과에 보는 바와 같이, 상기 실시예 1, 2, 3에 의해 추출된 속수자 추출물들(시료 1 내지 3)은 5α-리덕테이즈의 활성을 억제하여, 5α-리덕테이즈와 관련된 남성 호르몬인 다이하이드로테스토스테론의 생성량을 억제하는 효과가 있음을 알 수 있다. 또한, 실시예 1의 추출물(시료 1)이 5α-리덕테이즈와 관련된 남성 호르몬인 다이하이드로테스토스테론의 생성량을 가장 많이 억제하는 효과가 있음을 알 수 있다.As can be seen from the above results, the extracts (samples 1 to 3) extracted by Examples 1, 2, and 3 inhibit the activity of 5α-reductase, and are dies which are male hormones related to 5α-reductase. It can be seen that there is an effect of suppressing the amount of hydrotestosterone produced. In addition, it can be seen that the extract of Example 1 (sample 1) has the most inhibitory effect on the amount of production of dihydrotestosterone, a male hormone associated with 5α-reductase.
<실험 2; 면포억제 시험>Experiment 2; Cotton Inhibition Test>
토끼의 귀에 면포 유발물질을 처리하면 1주일 경과 후부터는 면포가 커지는데 일반적으로 면포가 커지는 것은 여드름의 염증이 일어나기 전단계와 같은 양상이다. 면포가 커지면서 모공 내에는 피지가 과량 들어 있게 되고 이로 인해 모공도 정상적인 상태보다 넓어지게 된다. 따라서, 면포발생 실험은 사람에서의 여드름효과와는 다소 다르지만 현재로서 모공을 넓게 유도해 할 수 있는 가장 근접한 실험방법이다.Treating a cotton-causing agent in the rabbit's ears will cause the cotton to grow after one week, but the larger cotton usually looks the same as before acne's inflammation. As the cotton cloth grows, there is an excessive amount of sebum in the pores, which causes the pores to be wider than normal. Therefore, the scleroderma experiment is somewhat different from the acne effect in humans, but at present it is the closest experimental method that can induce wide pores.
실시예 1에서 추출된 속수자 추출물(시료 1)이 면포억제 효능이 있는지 확인하고자 다음과 같은 실험을 하였다.In order to determine whether the extract of Soukja extract (sample 1) extracted in Example 1 was effective in suppressing cotton cloth, the following experiment was performed.
1) 흰토끼의 귀에 면포 유발 물질인 50올레익산/파라핀오일을 150㎕씩 하루 1번 도포하여 면포를 유발시킴과 동시에, 실시예 1의 속수자 추출물(시료 1)을 화장품 원료이며 면포를 유발하지 않는 1.3-BG에 1로 녹여, 오후에 2번 0.2㎖씩 도포해 주었다.1) 150 μl of 50-oleic acid / paraffin oil, which is a cotton-causing substance, is applied to the ears of white rabbits once a day to induce cotton cloth. 1, dissolved in 1.3-BG, 0.2 ml twice was applied in the afternoon.
2) 대조군으로, 면포 유발물질인 올레익산을 처리하지 않은 군(대조군 1)과 올레익산을 처리하고 속수자 추출물은 바르지 않은 군(대조군 2)으로 설정하여 실험하였다.2) As a control group, the group was treated with oleic acid, which was not treated with the oleic acid (control group 1), and treated with oleic acid, and the extract was treated with the group that was not applied (control group 2).
3) 면포의 수는 면포의 크기가 0.2㎜ 이상되는 것을 기준으로 삼았다.3) The number of cotton cloth was based on the size of the cotton cloth being 0.2 mm or more.
4) 면포발생부위의 조직을 0.8㎜ 절편하여 각질을 벗겨낸 후, 광학현미경으로 면포의 크기를 측정하였다. #1-6은, 면포의 크기를 측정하기 위해 절편한 조직에서 전체 면포들 중 면포가 잘 발달된 것들 중에서 무작위로 6개를 선정해 면포 크기를 측정한 것이다. 그 결과는 표 3에 나타나 있다.4) After exfoliation of the tissues of the scalp generating site by 0.8 mm, the keratin was removed, and the size of the scalp was measured by an optical microscope. # 1-6 is to measure the size of the cotton cloth by randomly selecting six of the well-developed cotton cloths from the sliced tissue. The results are shown in Table 3.
N: 동물 마리 수N: number of animals
#1-6: 면포 크기를 측정하기 위해 선정된 6개 면포의 일련번호# 1-6: Serial number of six cotton cloths selected for measuring cotton size
토끼를 이용한 동물실험에서, 면포유발물질 처리 후 속수자추출물을 도포한 경우에는 2주후부터는 점차적으로 면포의 수 및 크기가 감소하는 양상을 보여주었다.In animal experiments with rabbits, the number and size of cotton cloth gradually decreased from 2 weeks after application of the extracts.
또한, 표 3에서 알 수 있듯이, 본 발명에 따른 속수자추출물이 면포의 발생을 억제하는 효과가 있음을 확인할 수 있다. 즉 면포의 수와 크기가 줄어드는 것은 여드름에 대한 효과뿐만 아니라 피지 과분비로 인해 모공이 넓어진 사람에서도 모공의 크기 감소시킬 수 있다는 간접적인 결과를 추정할 수 있다.In addition, as can be seen in Table 3, it can be confirmed that the extracts according to the present invention has an effect of suppressing the generation of cotton cloth. In other words, the reduction in the number and size of cotton cloth can be inferred from the effects on acne, as well as the reduction in pore size in people with enlarged pores due to sebum oversecretion.
<실험 3; 여드름 효과>Experiment 3; Acne Effect>
여드름으로 고민하는 남녀 10명(표 4)을 선정하여 상기 실시예 4의 처방에 따른 유연화장수로 아침, 저녁 4주간 여드름 부위와 얼굴의 피지 분비가 많은 곳을 매일 바르게 하였다. 효과의 판정은 시험에 참가한 본인이 느끼는 정도에 따라 점수화하였다.Ten men and women who suffer from acne (Table 4) were selected and softened according to the prescription of Example 4, and the sebum secretion of the acne and facial lotion for 4 weeks in the morning and evening were corrected daily. Judgment of the effect was scored according to the degree felt by the person who participated in the test.
실험결과는 표 4에 나타나 있다.The experimental results are shown in Table 4.
시험 전 상태: 1 = 여드름 조금 있음Pre-test status: 1 = slight acne
2 = 약간 있음2 = slightly
3 = 여드름 심함3 = severe acne
효과 판정: - : 효과 거의 없음Effectiveness judgment:-: Almost no effect
+ : 약간의 효과 있음+: Has some effect
++ : 많이 완화++: eased a lot
+++: 완전히 치유됨+++: completely healed
<실험 4; 피지분비 억제>Experiment 4; Sebum Secretion Suppression>
속수자 추출물이 피지분비를 억제하는지 여부 및 그 정도를 확인하고자 얼굴에 피지분비가 많다고 느끼는 남녀 6명을 다음과 같은 실험을 하였다.The following experiment was conducted on six men and women who felt sebum secretion on the face to determine whether and how the extracts inhibit sebum secretion.
1) 매일저녁 세안 후 실시예 4의 유연화장수를 한달 동안 바랐다.1) After washing the face every evening, the flexible longevity of Example 4 was hoped for a month.
2) 피지 측정은 세안 후 30분간 항온 항습실에서 안정시킨 후 피지측정기(Sebumeter)를 이용하여, 이마와 뺨, 턱의 3부위의 피지량을 측정하였다.2) Sebum measurement was stabilized in a constant temperature and humidity room for 30 minutes after washing the face, and then sebum was measured at the three parts of the forehead, cheek, and chin by using a sebumeter.
속수자 추출물 사용 전에 측정된 피지량을 초기값으로 설정하였다. 속수자 추출물을 함유한 유연화장수(실시예 4)를 지속적으로 사용하면서, 매주 1회, 4주간 피지량을 측정하였다.The amount of sebum measured before use of the extract was set to the initial value. Sebum amount was measured once a week for 4 weeks while continuously using the softening water (Example 4) containing a water extract.
3) 초기값과 비교하여 속수자 추출물을 함유한 유연화장수의 피지 억제 효능 여부를 판정하였는데 그 결과는 표 5에 나타나 있다.3) Compared with the initial value, it was determined whether sebum inhibiting efficacy of softener longevity containing water extract is shown in Table 5.
표 4및 표 5에 나타난 결과에 나타난 바와 같이, 속수자 추출물을 함유한 유연화장수는 여드름이 악화되는 것을 감소시킴과 함께 피지분비로 고민하는 사람들에서도 얼굴 각 부위에서의 피지 분비를 억제시키는 것을 확인하였다.As shown in the results shown in Tables 4 and 5, the softening water containing the extract of Sotoja reduced acne worsening and inhibited sebum secretion in each part of the face even in those suffering from sebum secretion. .
본 발명에 따른 실시예 및 실험에서 볼 수 있는 바와 같이, 본 발명에 의해 제공되는 속수자 추출물은, 5α-리덕테이즈 저해효과가 뛰어날 뿐만 아니라 화장료 조성물로서 사람에게 사용했을 때 여드름 완화 및 피지분비 감소의 효과가 우수하다. 따라서, 본 발명에 따른 속수자 추출물은 제품의 안전성 영향을 미치지 않는 농도에서 여드름 완하 효과 또는 피지분비 억제 효과가 있으므로 피지억제 화장료 또는 여드름 완하 화장료에 유효농도로 사용될 수 있고, 피부도포용 의약품의 일반적인 제형에 유효성분으로 사용될 수 있다.As can be seen in the examples and experiments according to the present invention, the water extracts provided by the present invention not only have an excellent 5α-reductase inhibitory effect but also reduce acne and reduce sebum secretion when used as a cosmetic composition in humans. The effect is excellent. Therefore, the water extract according to the present invention has an acne laxative effect or sebum secretion inhibitory effect at a concentration that does not affect the safety of the product, so it can be used as an effective concentration in sebum inhibitory cosmetics or acne laxative cosmetics, and general dosage forms of medicines for skin application It can be used as an active ingredient in.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990028078A KR100310613B1 (en) | 1999-07-12 | 1999-07-12 | Euphorbia Lathyris extract inhibiting the activity of 5a-reductase, and the cosmetic or skincare-pharmaceutical composition thereof for suppressing pimple or sebum |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019990028078A KR100310613B1 (en) | 1999-07-12 | 1999-07-12 | Euphorbia Lathyris extract inhibiting the activity of 5a-reductase, and the cosmetic or skincare-pharmaceutical composition thereof for suppressing pimple or sebum |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010009623A KR20010009623A (en) | 2001-02-05 |
KR100310613B1 true KR100310613B1 (en) | 2001-10-12 |
Family
ID=19601147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019990028078A KR100310613B1 (en) | 1999-07-12 | 1999-07-12 | Euphorbia Lathyris extract inhibiting the activity of 5a-reductase, and the cosmetic or skincare-pharmaceutical composition thereof for suppressing pimple or sebum |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100310613B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100770123B1 (en) * | 2001-11-06 | 2007-10-24 | 주식회사 엘지생활건강 | Nanoemulsion cosmetic composition for whitening containing 5,15-diacetyl-3-benzoyllathyrol |
KR100770122B1 (en) * | 2001-11-06 | 2007-10-24 | 주식회사 엘지생활건강 | Liquid crystal gel cosmetic composition for whitening containing 5,15-diacetyl-3-benzoyllathyrol |
WO2015152564A1 (en) * | 2014-04-01 | 2015-10-08 | 코스맥스 주식회사 | Cosmetic composition for preventing or alleviating sensitive skin, containing mixture extraction oil of euryale ferox salisb., euphorbia lathyris l. and rosa multiflora thunb. |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100613266B1 (en) * | 1999-09-21 | 2006-08-18 | 주식회사 엘지생활건강 | Stratum corneum delamination promoting agent and medicine or cosmetic material containig the same |
KR100502072B1 (en) * | 2002-07-09 | 2005-07-25 | 주식회사 태평양 | 5α-reductase inhibitors containing lathyrane diterpene and skin care and pharmaceutical compositions for external applications containing thereof |
-
1999
- 1999-07-12 KR KR1019990028078A patent/KR100310613B1/en not_active IP Right Cessation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100770123B1 (en) * | 2001-11-06 | 2007-10-24 | 주식회사 엘지생활건강 | Nanoemulsion cosmetic composition for whitening containing 5,15-diacetyl-3-benzoyllathyrol |
KR100770122B1 (en) * | 2001-11-06 | 2007-10-24 | 주식회사 엘지생활건강 | Liquid crystal gel cosmetic composition for whitening containing 5,15-diacetyl-3-benzoyllathyrol |
WO2015152564A1 (en) * | 2014-04-01 | 2015-10-08 | 코스맥스 주식회사 | Cosmetic composition for preventing or alleviating sensitive skin, containing mixture extraction oil of euryale ferox salisb., euphorbia lathyris l. and rosa multiflora thunb. |
KR20150114622A (en) | 2014-04-01 | 2015-10-13 | 코스맥스 주식회사 | Cosmetic composition for prevention or improvement of sensitive skin comprising mixture oil extracted of Euryale ferox, Euphorbia lathyris L. and Rosa multiflora fruit |
KR101597505B1 (en) | 2014-04-01 | 2016-02-26 | 코스맥스 주식회사 | Cosmetic composition for prevention or improvement of sensitive skin comprising mixture oil extracted of Euryale ferox, Euphorbia lathyris L. and Rosa multiflora fruit |
Also Published As
Publication number | Publication date |
---|---|
KR20010009623A (en) | 2001-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3529811B2 (en) | External preparation for skin | |
JP3415199B2 (en) | External preparation for skin | |
JP3415197B2 (en) | External preparation for skin | |
JPH08119825A (en) | Hydroxytyrosol, application for skin external medicine or bathing agent | |
JP3407935B2 (en) | External preparation for skin | |
KR102271886B1 (en) | Cosmetic composition containing complex medicinal herbs extract for skin whitening and anti-wrinkle effect and manufacturing method thereof | |
KR101975951B1 (en) | Manufacturing Method of Japanese Rose Flower Extract and Rose Flower Extract for Whitening Cosmetic Preparations containing these Extracts | |
US6299885B1 (en) | External preparations containing watercress extract | |
JPH0930946A (en) | Beautifying and whitening dermal preparation for external use | |
KR100310613B1 (en) | Euphorbia Lathyris extract inhibiting the activity of 5a-reductase, and the cosmetic or skincare-pharmaceutical composition thereof for suppressing pimple or sebum | |
KR102101949B1 (en) | A skin-care agent or cosmetics containig Antrodia camphorata fruit body extract or Antrodia camphorata mycelium extract | |
KR101252550B1 (en) | Cosmetic composition for protecting sebum secretion on the skin | |
JPH0812561A (en) | Beautifying and whitening skin preparation for external use | |
KR20090032583A (en) | ALPINIA OFFICINARUM EXTRACT FOR INHIBITING OF 5alpha;-REDUCTASE ACTIVITY AND COSMETIC COMPOSITION FOR INHIBITING OF SEBUM SECRETION OR IMPROVING OF ACNES | |
KR20020001911A (en) | Cosmetic composition containing portulaca oleracea L. extract for anti-inflammation and anti-irritation | |
JP2001187742A (en) | Testosteron-5-alfa-reductase inhibitor | |
KR20030039726A (en) | A cosmetic composition containing an extract of petasites japonicus | |
JP4197194B2 (en) | Oral administration agent for intercellular adhesion suppression | |
WO2000071092A1 (en) | Skin whitener | |
JP2001181129A (en) | Collagenase activity inhibitor | |
KR100368126B1 (en) | Composition capable of inhibiting sebum secretion | |
KR100927970B1 (en) | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition | |
KR102186533B1 (en) | A cosmetic composition for skin whitening comprising Rosa Damascena Flower Oil and Rhodiola Rosea root extract | |
JPH0930948A (en) | Beautifying and whitening dermal preparation for external use | |
KR102342410B1 (en) | Extraction method of Lotus corniculatus Var. japonicus, its extracts and Cometic composition consisting of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120824 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20130813 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20140829 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20150901 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20160624 Year of fee payment: 16 |
|
LAPS | Lapse due to unpaid annual fee |